GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (NAS:BTAI) » Definitions » 5-Year ROIIC %

BTAI (BioXcel Therapeutics) 5-Year ROIIC % : -8,737.10% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. BioXcel Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was -8,737.10%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for BioXcel Therapeutics's 5-Year ROIIC % or its related term are showing as below:

BTAI's 5-Year ROIIC % is ranked worse than
99.31% of 1301 companies
in the Biotechnology industry
Industry Median: -22.17 vs BTAI: -8737.10

BioXcel Therapeutics 5-Year ROIIC % Historical Data

The historical data trend for BioXcel Therapeutics's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics 5-Year ROIIC % Chart

BioXcel Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year ROIIC %
Get a 7-Day Free Trial - - -1,522.82 -1,738.29 -8,737.10

BioXcel Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -8,737.10 - - -

Competitive Comparison of BioXcel Therapeutics's 5-Year ROIIC %

For the Biotechnology subindustry, BioXcel Therapeutics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioXcel Therapeutics's 5-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioXcel Therapeutics's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's 5-Year ROIIC % falls into.



BioXcel Therapeutics 5-Year ROIIC % Calculation

BioXcel Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -167.619 (Dec. 2023) - -19.962 (Dec. 2018) )/( 2.068 (Dec. 2023) - 0.378 (Dec. 2018) )
=-147.657/1.69
=-8,737.10%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


BioXcel Therapeutics  (NAS:BTAI) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


BioXcel Therapeutics 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioXcel Therapeutics Business Description

Traded in Other Exchanges
Address
555 Long Wharf Drive, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Executives
Richard I Steinhart officer: Chief Financial Officer 125 ELM STREET, NEW CANAAN CT 06840
Matthew T. Wiley officer: CHIEF COMMERCIAL OFFICER C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402
Javier Rodriguez officer: SEE REMARKS C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Frank Yocca officer: Chief Scientific Officer 780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Vincent O'neill officer: Chief Medical Officer 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Vimal Mehta director, officer: CEO, President, Secretary 780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Krishnan Nandabalan director, 10 percent owner 228 VILLAGE POND ROAD, GUILFORD CT 06437
Alka Sood 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Michael James Aiello 10 percent owner 10 TEMPLETON ROAD, WALLINGFORD CT 06492
Pardeep Kumar Sood 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Vipin Agarwal 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Rashmi Agarwal 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Jatin Markand Patel 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Bina Jatin Patel 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Diwakar Jain 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437